Haleon nabs finance chief from Tate & Lyle as CFO steps down
Haleon
329.90p
16:45 03/05/24
The chief financial officer of consumer health company Haleon is to step down after three years and will be replaced by Tate & Lyle's CFO Dawn Allen.
Food Producers & Processors
8,125.63
16:54 03/05/24
FTSE 100
8,213.49
16:59 03/05/24
FTSE 250
20,164.54
17:00 03/05/24
FTSE 350
4,515.50
16:54 03/05/24
FTSE All-Share
4,469.09
17:14 03/05/24
Pharmaceuticals & Biotechnology
23,112.61
16:54 03/05/24
Tate & Lyle
655.00p
16:40 03/05/24
The company, known for brands like Sensodyne, Centrum and Panadol, announced on Wednesday that Tobias Hestler has decided to leave "to better balance work demands with the management of a long-term health condition".
He will leave the company in November, having served nearly three years after joining in December 2021.
Hestler will be succeeded by Dawn Allen, the current CFO at Tate & Lyle and former CFO at Mars Inc, who also serves on the board at ITV.
Allen, who will receive an annual salary of £730,000 along with an annual bonus and long-term incentive plans, has "extensive consumer and international experience and will be a great addition to our executive team", said Haleon's chief executive Brian McNamara.
Allen said she was "very excited" to join Haleon. "Its clear purpose and fascinating journey through separation and beyond sets a strong foundation for the future. I am looking forward to help shape the next phase of the journey," she said.
In a separate statement, ingredients group Tate & Lyle said: "The board has begun a process to appoint a successor to Mrs Allen and a further announcement will be made in due course."